VectivBio Holding AG Ordinary Shares
VECT
VECT was delisted on the 7th of July, 2023.
22 hedge funds and large institutions have $150M invested in VectivBio Holding AG Ordinary Shares in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
37% more capital invested
Capital invested by funds: $110M → $150M (+$40.6M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
29% more funds holding
Funds holding: 17 → 22 (+5)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$6.15M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$4.1M |
| 3 |
CA
CHI Advisors
New York
|
+$3.76M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$2.71M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$2.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$460K |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$220K |
| 3 |
Millennium Management
New York
|
-$57K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$11K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$5.92K |
VECT Hedge Fund Activity: Q2 2022 in Review
22 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in VectivBio Holding AG Ordinary Shares (VECT) for Q2 2022, worth a combined $150M — up 37% from $110M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new VECT positions and 1 closed out — a net gain of 5 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was OrbiMed, adding an estimated $6.15M. The largest seller was Bank of America, cutting an estimated $460K.
- 22 institutional investors held VectivBio Holding AG Ordinary Shares (VECT) as of Q2 2022, up from 17 in Q1 2022.
- Funds reported $150M of VectivBio Holding AG Ordinary Shares stock for Q2 2022, up 37% quarter-over-quarter.
- 6 funds opened new VectivBio Holding AG Ordinary Shares positions in Q2 2022 and 1 closed out, a net change of +5 holders.
- The largest VectivBio Holding AG Ordinary Shares buyer in Q2 2022 was OrbiMed, an estimated $6.15M added.
- The largest VectivBio Holding AG Ordinary Shares seller in Q2 2022 was Bank of America, an estimated $460K sold.
Based on aggregated 13F filings for Q2 2022.